Analysis of correlation between serum thymidine kinase 1 and acute myeloid leukemia.
10.7534/j.issn.1009-2137.2013.05.002
- Author:
Ting-Jing WANG
1
,
2
;
Ai-Ning SUN
;
De-Pei WU
;
Wei-Yang LI
;
Jian-Ying LIANG
Author Information
1. Jiangsu Institute of Hamatology, Department of Hematology, The First Affiliated Hospital of Soochow University
2. Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, Jiangsu Province, China.
- Publication Type:Journal Article
- MeSH:
Adolescent;
Adult;
Aged;
Case-Control Studies;
Female;
Humans;
Leukemia, Myeloid, Acute;
blood;
Male;
Middle Aged;
Thymidine Kinase;
blood;
Young Adult
- From:
Journal of Experimental Hematology
2013;21(5):1095-1098
- CountryChina
- Language:Chinese
-
Abstract:
This study was purposed to investigate the clinical significance of serum thymidine kinase 1 (STK1) level change in acute myeloid leukemia (AML). Peripheral blood samples of 60 newly diagnosed AML patients were collected and the STK1 levels were determined by enhanced chemiluminescent dot-blot method before and at two weeks after start of inductive treatment and in consolidatory treatment. Using non-parametric test, the differences between groups were analyzed. Then the correlation between STK1 level and clinical characteristics was explored by a way of chi-square test. The results indicated that the serum TK1 level in complete remission (CR) or partial remission (PR) AML patients decreased in varying degree as compared to pretreatment (P < 0.05), while there was no significant difference of TK1 level in non-remission (NR) ones (P > 0.05). The serum TK1 level in CR patients remained low level but increased noticeably after relapse into progressive disease (P < 0.05). A significant correlation was found between STK1 level and chromosomal abnormalities, serum LDH level as well as whether had fever in de novo AML patients (P < 0.05). It is concluded that the serum TK1 level change may be applied for reflecting the aggressiveness of disease, monitoring the clinical response to chemotherapy, evaluating the prognosis and predicating the relapse risk. The decrease of TK1 level suggests effective treatment and tumor burden reduction, while its increase indicate poor prognosis and relapse risk.
